Causaly has introduced a new artificial intelligence system that it says it believes is the first agentic AI platform designed specifically for life sciences research and development. Called Causaly Agentic Research, the technology builds on the company’s earlier Deep Research product and aims to address long-standing inefficiencies in how scientists search, analyse and interpret biomedical knowledge.

The platform uses specialised AI agents trained to complete multi-step research tasks, from generating hypotheses and testing them to producing structured, evidence-backed outputs that can withstand regulatory scrutiny. According to the company, this approach can reduce the time needed for data analysis, speed up decision-making, and cut reliance on manual literature reviews or fragmented tools. The interface allows scientists to interact directly with research agents, creating what Causaly describes as a single source of truth that integrates internal and external data as well as competitive intelligence.

Yiannis Kiachopoulos, co-founder and chief executive of Causaly, said: “Agentic AI fundamentally changes how life sciences conducts research. Causaly Agentic Research emulates the scientific process, automatically analyzing data, finding biological relationships, and reasoning through problems. AI agents work like digital assistants, eliminating manual tasks and dependencies on other teams, so scientists can access more diverse evidence sources, de-risk decision-making, and focus on higher-value work.”

The launch comes at a time when research and development groups are struggling to manage the growing volume of biomedical information. Teams often spend weeks analysing limited datasets, while key insights may remain hidden. Siloed workflows and human bias can also influence the outcomes of discovery work, slowing the pace of new treatments reaching patients. Causaly claims its platform addresses these challenges by continuously scanning the scientific landscape, surfacing new signals in real time, and ensuring findings are transparent and traceable.

As part of the wider Causaly platform, the agentic system is designed to connect with internal company systems, public databases, and even other AI tools, providing a unified environment for research. By offering traceable, evidence-backed results, the company argues the platform can improve the productivity of R&D teams while maintaining the scientific rigour needed for regulatory approval.

Causaly said it expects the platform to be applied across drug discovery and development workflows, from early target identification through to clinical development planning. With pressure on the life sciences industry to shorten timelines and manage ever larger datasets, agentic AI approaches are likely to draw close attention from researchers and decision-makers alike.